Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Chemo BrainChemotherapy-related Cognitive ImpairmentChemo FogBreast CancerChemobrain
Interventions
DRUG

Transdermal nicotine

Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.

OTHER

Placebo Transdermal Patch

Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.

Trial Locations (1)

37212

Center for Cognitive Medicine at Vanderbilt University, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER

NCT02312934 - Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study | Biotech Hunter | Biotech Hunter